Abstract
Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Volume: 12 Issue: 3
Author(s): Pinar Kuru and Mehmet Agirbasli
Affiliation:
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Abstract: Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Export Options
About this article
Cite this article as:
Kuru Pinar and Agirbasli Mehmet, Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692112666141027231225
DOI https://dx.doi.org/10.2174/1875692112666141027231225 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patenting Penicillium Strains
Recent Patents on Biotechnology Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Heart Failure in the Middle East
Current Cardiology Reviews Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Mini-Reviews in Medicinal Chemistry Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets The Vectorcardiogram and the Main Dromotropic Disturbances
Current Cardiology Reviews Carbon Nanotube-Based Electrochemical Biosensing Platforms: Fundamentals,Applications, and Future Possibilities
Recent Patents on Biotechnology Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Fundamental Concepts of the Angiogenic Process
Current Molecular Medicine The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
Current Respiratory Medicine Reviews Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design Virtual Screening Strategies in Medicinal Chemistry: The State of the Art and Current Challenges
Current Topics in Medicinal Chemistry Chronic Kidney Disease - Different Role for HDL?
Current Medicinal Chemistry